Featured Research

from universities, journals, and other organizations

Mayo Clinic Researchers Develop New Treatment For Incurable Recurring Form Of Adult Brain Cancer

Date:
May 17, 2005
Source:
Mayo Clinic
Summary:
A study led by Mayo Clinic researchers and conducted by the North Central Cancer Treatment Group (NCCTG) reports that a new "smart" drug treatment for an incurable form of recurrent brain cancer slowed tumor growth in more than one-third of the 65 adult patients who tried it. The same research team also developed a screening technique to help predict which patients will respond best to this treatment.

ROCHESTER, Minn. -- A study led by Mayo Clinic researchers and conducted by the North Central Cancer Treatment Group (NCCTG) reports that a new "smart" drug treatment for an incurable form of recurrent brain cancer slowed tumor growth in more than one-third of the 65 adult patients who tried it. The same research team also developed a screening technique to help predict which patients will respond best to this treatment.

Mayo researchers will present these findings at the 2005 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla. The NCCTG study addressed the most common kind of tumor arising from brain tissue of adults, glioblastoma mutiforme. Current treatment outcomes for this type of cancer are extremely poor: median patient survival is 12 to 16 months, and recurrent disease has a dismal prognosis. The World Health Organization categorizes fast-growing glioblastoma multiforme as a grade IV cancer.

Significance of the Mayo Clinic/NCCTG Research

This discouraging prognosis may change as a result of the rational foundation for new therapies the NCCTG research provides. Study data showed that in 36 percent of patients suffering from recurrent glioblastoma multiforme, the new "smart" drug behaved as hypothesized: It found its target -- tumor cells -- and actively worked against them to slow tumor growth.

According to the study's lead investigator, Mayo Clinic medical oncologist Evanthia Galanis, M.D., "Treatment was well tolerated, and imaging responses were observed in a significant portion (36 percent) of patients with recurrent glioblastoma multiforme participating in this study -- which is a high response rate for this very resistant disease. These early results suggest that we are on to a promising new treatment strategy that could potentially help us improve treatment for patients with recurrent glioblastoma."

Achieving the 36 percent regression rate was an encouraging result -- but researchers didn't stop there. They took the work a step further by analyzing specific tumor properties of the patients enrolled in the study. What they found is also encouraging. Patients most likely to respond well to the drug shared a common feature -- activation of a specific tumor protein, p70s6 kinase, which is closely associated with the drug target molecule.

Knowing that this protein is a key player in the chain of events that determines drug activity could be useful in screening patients to help determine the best candidates for the drug. Says Dr. Galanis, "This could allow us to customize drug administration to the patients most likely to benefit from it, and in that way, improve care."

A Smart Drug

In their study, NCCTG researchers used an investigational drug that is not currently available for wide use. Known as CCI-779, or temsirolimus, it is a "smart" drug in the sense that it has been designed to target specific changes in the glioblastoma multiforme tumor cells that previous studies have identified as key factors in the tumor's aggressive behavior.

About Glioblastoma Multiforme

In adults, glioblastoma multiforme is the most common form of brain tumor. Because it originates in the brain, physicians refer to it as a primary tumor. This is in contrast to a tumor that develops in the brain from cancer cells that have spread from tumors elsewhere in the body. Glioblastoma multiforme accounts for more than 50 percent of the estimated 18,000 primary malignant brain tumors diagnosed each year in the United States. When first diagnosed, glioblastoma multiforme is usually treated with surgery, radiation therapy and chemotherapy -- and median survival is 12 to 16 months. For patients in whom the disease recurs, the prognosis is indeed dismal: there are no good treatment options.

The Next Step

Mayo Clinic researchers are continuing to investigate the implications of their findings. NCCTG studies now under way will test the combination of CCI-779 with radiation therapy in patients who have newly diagnosed glioblastoma multiforme. They will also test CCI-779 in combination with other targeted therapies in patients with recurrent cases of glioblastoma multiforme.

Collaboration and Support

In addition to Dr. Galanis, Mayo Clinic research team members included Jan Buckner, M.D.; Matthew Maurer, M.S.; Brad Erickson, M.D., Ph.D.; Bernd Scheithauer, M.D.; Robert Jenkins, M.D., Ph.D.; and Karla Ballman, Ph.D. External collaborators included researchers from Johns Hopkins University and the University of Texas, San Antonio.

###

DISCLOSURE: This study was supported by grants from the National Cancer Institute (NCI) and coordinated by the North Central Cancer Treatment Group (NCCTG), a national clinical research group sponsored by the NCI. NCCTG is a network of more than 400 community-based cancer treatment clinics in the United States, Canada and Mexico that work with Mayo Clinic to conduct clinical studies for advancing cancer treatment.



Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Mayo Clinic Researchers Develop New Treatment For Incurable Recurring Form Of Adult Brain Cancer." ScienceDaily. ScienceDaily, 17 May 2005. <www.sciencedaily.com/releases/2005/05/050517111516.htm>.
Mayo Clinic. (2005, May 17). Mayo Clinic Researchers Develop New Treatment For Incurable Recurring Form Of Adult Brain Cancer. ScienceDaily. Retrieved September 21, 2014 from www.sciencedaily.com/releases/2005/05/050517111516.htm
Mayo Clinic. "Mayo Clinic Researchers Develop New Treatment For Incurable Recurring Form Of Adult Brain Cancer." ScienceDaily. www.sciencedaily.com/releases/2005/05/050517111516.htm (accessed September 21, 2014).

Share This



More Health & Medicine News

Sunday, September 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins